ALK8700-A302, an Evolve-MS Clinical Study, is taking place at Meridien Research in Tampa. This research study is evaluating an experimental drug for people who have been diagnosed with RRMS.
To be eligible for this study, you must:
- Be 18 to 65 years of age
- Have been diagnosed with RRMS
- Not have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
- Not have a gastrointestinal disorder like stomach ulcers, inflammatory bowel disease, or irritable bowel syndrome
Other criteria apply. All study-related visits, tests, and study drugs (ALKS 8700 and Tecfidera) will be provided at no cost to you. In addition, reimbursement for travel-related expenses may be provided.
How can I participate in the ALK8700-A302 study?
To learn more about this study, or to find out if you may qualify, please contact Beth at 813-877-8839 or complete the form below.